Collegium Pharmaceutical Inc (COLL)

[floblu14]

Joe - our stock is significantly undervalued

New Slide show -
https://ir.collegiumpharma.com/static-files/9c4d7cfd-22fd-4912-a3e2-ad94b4aa0bb8

[floblu14]

Do Options Traders Know Something About Collegium Pharmaceutical (COLL) Stock We Don't? June 22

Excerpts:

Investors in Collegium Pharmaceutical, Inc. COLL need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 15, 2023 $35.00 Call had some of the highest implied volatility of all equity options today.

Clearly, options traders are pricing in a big move for Collegium Pharmaceutical shares....

Given the way analysts feel about Collegium Pharmaceutical right now, this huge implied volatility could mean there’s a trade developing.

https://finance.yahoo.com/news/options-traders-know-something-collegium-123000185.html

[floblu14]

What company are they planning to purchace?
New career opportunities - excerpts:

Senior Quality Assurance Specialist[/b
The Sr. Quality Assurance Specialist on the Quality team at Collegium will be responsible for supporting the manufacturing, testing, and disposition of drug products for commercial use, as well as providing support in the management of critical quality systems. This includes oversight of quality records including change controls, executed batch records, deviations and quality assurance representation during commercial launch activities, particularly as they pertain to Collegium’s GMP virtual manufacturing.

RESPONSIBILITIES -
In-depth knowledge and understanding of FDA expectations, specifically as they relate to batch disposition.

https://boards.greenhouse.io/collegiumpharma/jobs/4244371006

[floblu14]

Takeaways from the Jeffries' CC today -

1. If COLL does nothing, they'll have over $1B cash by 2027

2. If COLL was not seen as an Opioid Company, they would have been acquired already

3. there is a disconnect between the company's current share price & its equity/worth

[floblu14]

"This will be a BANNER YEAR" - quote - JOE C. ad nauseam.......

a banner year....................................

Yes - a BANNER YEAR for the OFFICERS & DIRECTORS, NOT THE SHAREHOLDERS!!!!!

[floblu14]

Collegium to Participate in Jefferies Healthcare Conference
June 1, 2023

STOUGHTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference being held in New York, NY from June 7-9, 2023.

Details of the event are as follows:
Fireside Chat Date and Time: Thursday, June 8, 2023, at 12:30 p.m.

https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-participate-jefferies-healthcare-conference

[floblu14]

Stock Analyst Reiterates Buy Rating on Collegium Pharmaceutical with 35 Price Target - May 30

On May 30, 2023, Serge Belanger, a stock analyst at Needham, reiterated his Buy rating on Collegium Pharmaceutical (NASDAQ: COLL) and maintained a $35 price target. This indicates that Belanger believes the stock is undervalued and has the potential to increase in value. This rating and price target were reaffirmed after the company’s Q1 2023 earnings call. Belanger specializes in analyzing the pharmaceutical industry.

https://beststocks.com/stock-analyst-reiterates-buy-rating-on-colleg/

[floblu14]

SEC Filing Details
Document Details
Form 144
Filing Date May 30, 2023
Document Date May 30, 2023
Form Description Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing
Filing Group Other
Company Collegium Pharmaceutical Inc.

https://ir.collegiumpharma.com/node/11431/html

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the
securities to be sold which has not been publicly disclosed.

Joseph Ciaffoni to sell 31+K shares of restricted stock (as previous compensation) - Form 144

https://ir.collegiumpharma.com/static-files/b15d389a-6e60-4a63-95ab-49ff5790b08f

The BIG question is - when will Mr. Ciaffoni et al BUY shares of the company on the open market - particularly this BANNER YEAR??

[floblu14]

Collegium: Turning More Constructive, Especially At 4.4x Earnings
May 25, 2023 8:14 AM ETCollegium Pharmaceutical, Inc. (COLL)
Zach Bristow

2.84K Followers
Summary
I am turning more constructive on Collegium following the outlook on its Q1 numbers.

It came in with record product revenues, the perfect complement to the excellent returns on capital invested.

The market expectations for COLL going forward are mispriced in my opinion.

Investment Summary
Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) underperformed the last quarter in-line with my neutral rating on the company back in January. Rolling forward 1 period, I am turning more constructive on the company. I am thus recommending an early buy of the stock at ultra-compressed multiples of 4.4x forward earnings for reasons discussed in this report.

There is plenty to like about COLL, its operations are of the healthy type - record Q1 product revenues, strong returns on capital, and plenty of cash flow to throw off to shareholders. One pullback, is that management haven't reinvested persistently back into the business at these rates of return, suggesting there may be a lack of opportunities to do so. Subsequently, it has been difficult for COLL to catch a long-term bid in my opinion over recent years.

Its market valuation has been buoyant in FY'22-'23, as the firm remains diligently profitable, and growing its balance sheet. In my opinion, it comes back to the opportunities to reinvest capital to grow. For now, the undeniable strengths in the company's business, combined with strengthening core product trends, make COLL investment grade at this point in time. I revise my rating on COLL to a buy.Net-net, revise to buy.

Read more:

https://seekingalpha.com/article/4607278-collegium-turning-more-constructive-4-4x-earnings

[floblu14]

Pain is most common chronic ailment in US

Karen Weintraub

USA TODAY May 22

Pain is the most common chronic ailment in America by far, a new study finds, and people in pain tend to stay in pain over the course of a year.

The study, published last week in JAMA Network Open, compared the pain scores of more than 10,000 people from 2019 to 2020.

Pain was found to be far more common than other chronic diseases. If 1,000 people were measured for a year, the study said, there would be 52 cases of chronic pain, 45 cases of high blood pressure, 16 cases of depression and seven cases of diabetes.

Volunteers were asked several questions: “In the past 3 months, how often did you have pain? Would you say never, some days, most days, or every day?” and “Over the past 3 months, how often did pain limit your life or work activities? Would you say never, some days, most days, or every day?”

At the start, about 40% reported no pain, about the same percentage reported some pain, and more than 20% reported chronic pain, suffering for at least the past three months.

In some cases, people recovered over the following year, while for others, their pain progressed. Nearly 15% of those with some pain in 2019 reported chronic pain a year later, while 10% of those reporting chronic pain in 2019 no longer had it the following year.

But the more pain someone was in in 2019, the more likely they were to still be suffering a year later and the greater their chances of having pain that limited their life or work activities.

Older people were more likely to report chronic pain than younger ones, and those without a college degree reported more pain than graduates.

Just over half the study volunteers were women, 54% were ages 18 to 49, and the rest were over 50. Just under 30% were college graduates. The group was roughly reflective of the broader population by race and ethnicity, with 2% American Indian or Alaska Native, 6% Asian, 12% Black, 73% white, and 17% identified as Hispanic.

Health and patient safety coverage at USA TODAY is made possible in part by a grant from the Masimo Foundation for Ethics, Innovation and Competition in Healthcare. The Masimo Foundation does not provide editorial input.

In some cases, people with chronic pain recovered over the following year, while for others, their pain progressed.

[floblu14]

Investors Eye Collegium Pharmaceutical’s Innovative Approach to Pharmaceuticals as Demand for Specialty Drugs Grows
by Yasmim Mendonça May 20, 2023

As the world grows increasingly reliant on pharmaceutical products, companies like Collegium Pharmaceutical, Inc. (NASDAQ: COLL) are in high demand. The specialty pharmaceutical company has caught the eye of institutional investor LPL Financial LLC, which recently increased its holdings in shares of Collegium Pharmaceutical, Inc. by 7%. According to the company’s most recent disclosure with the Securities and Exchange Commission, LPL Financial LLC now owns 151,463 shares of Collegium Pharmaceutical stock worth $3,514,000.

Collegium Pharmaceutical develops and commercializes abuse-deterrent products for chronic pain patients and others affected by various diseases. Its growing portfolio includes Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. This innovative approach to developing pharmaceuticals has helped them to stand out in an industry where cost-cutting measures usually account for drug development.

The market cap of Collegium Pharmaceutical currently stands at $779.54 million with a price-to-earnings ratio of -26.20 and a price-to-earnings-growth ratio of just 0.24 – indicating solid prospects for continued growth. Meanwhile, its beta stands at a modest 0.81 with both quick and current ratios above one – signifying that it has adequate resources to continue growing.

The company’s stock opened at $22.53 on Friday May 19th with a fifty-day simple moving average of $23.39 and a two-hundred-day simple moving average of $24.13; these figures demonstrate stability despite challenges posed by global economic downturns in recent years.

Despite recent volatility in financial markets worldwide caused by political tensions or pandemic fears across multiple global locations including Asia-Pacific region particularly India as well as Europe through new COVID variant outbreaks- investors’ confidence remains high regarding the future success of Collegium Pharmaceutical.

Read more:
https://beststocks.com/investors-eye-collegium-pharmaceuticals-innovativ/

[floblu14]

Collegium Pharmaceutical management to meet virtually with Needham.

Virtual Meeting to be held on May 24 hosted by Needham. Hopefully, we'll have the opportunity to listen.

Also, unfortunately, we were NOT able to attend the A/M, in person, & ask questions!

P.S. No career postings for a week now - quite unusual. M or A coming up??
https://boards.greenhouse.io/collegiumpharma

[floblu14]

Top Pharmaceutical Stocks for Q2 2023
Aclaris, Collegium, and Intra-Cellular lead the industry in revenue growth

By NOAH BOLTON Published May 18, 2023

Fastest-Growing Pharmaceutical Stocks

These are the top pharmaceutical stocks as ranked by a growth model that scores companies based on a 50/50 weighting of their most recent quarterly YOY percentage revenue growth and their most recent quarterly YOY earnings-per-share (EPS) growth.

Both sales and earnings are critical factors in the success of a company. Therefore, ranking companies by only one growth metric makes a ranking susceptible to the accounting anomalies of that quarter (such as changes in tax law or restructuring costs) that may make one or the other figure unrepresentative of the business in general. Companies with quarterly EPS or revenue growth of more than 1,000% were excluded as outliers.

Fastest-Growing Pharmaceutical Stocks
Price ($) Market Cap ($B) EPS Growth (%) Revenue Growth (%)
Aclaris Therapeutics Inc. (ACRS) 8.95 0.6 N/A (see company description) 417
Collegium Pharmaceutical Inc. (COLL) 22. 0.8 N/A (see company description) 374
Intra-Cellular Therapies Inc. (ITCI) 63.26 6.0 N/A (see company description)

Collegium Pharmaceutical Inc.: This is a pharmaceutical company that specializes in producing therapies for pain management. On May 4, the company released first-quarter earnings with a net loss widening to $17 million from $13 million a year ago. At the same time, it posted revenue growth of 73% from increased sales of Xtampza ER and Belbuca.

Note Collegium doesn't have an EPS growth figure in the table above because it reported a net loss per share in the most recent quarter

https://www.investopedia.com/top-pharmaceutical-stocks-q2-2023-7499241?utm_campaign=quote-yahoo&utm_source=yahoo&utm_medium=referral

[floblu14]

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2023 Earnings Call Transcript

https://finance.yahoo.com/news/collegium-pharmaceutical-inc-nasdaq-coll-191546956.html

[floblu14]

Collegium Pharmaceutical (NASDAQ:COLL – APRIL 21) - stock had its “buy” rating reaffirmed by equities research analysts at Needham & Company LLC in a report issued on Wednesday, Benzinga reports. They presently have a $35.00 target price on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price objective indicates a potential upside of 53.24% from the stock’s current price.

https://www.defenseworld.net/2023/04/21/collegium-pharmaceuticals-coll-buy-rating-reiterated-at-needham-company-llc.html

[floblu14]

FWIW - Based in Stoughton, MA we are a team of nearly 300 employees and growing.

https://boards.greenhouse.io/collegiumpharma/jobs/4138138006

[floblu14]

Collegium to Participate in 22nd Annual Needham Virtual Healthcare Conference
April 11, 2023

STOUGHTON, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the 22nd Annual Needham Healthcare Conference being held virtually from April 17-20, 2023.

Details of the event are as follows:
Fireside Chat Date and Time: Tuesday, April 18, 2023, at 2:15 p.m. ET

The fireside chat will be webcast live and can be accessed from the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-participate-22nd-annual-needham-virtual-healthcare

[floblu14]

Collegium Pharmaceutical management to meet with Piper Sandler

Meeting to be held in New York on March 30 hosted by Piper Sandler.

[floblu14]

Chronic pain patients struggle to get opioid prescriptions filled, even as CDC eases guidelines March 17, 2023

Layman is one of the millions in the U.S. living with chronic pain. Many have struggled to get opioid prescriptions written and filled since 2016 guidelines from the Centers for Disease Control and Prevention inspired laws cracking down on doctor and pharmacy practices. The CDC recently updated those recommendations to try to ease their impact, but doctors, patients, researchers, and advocates say the damage is done.

https://www.cnn.com/2023/03/17/health/opioid-chronic-pain-cdc-guidelines-khn-partner/index.html

This article today should have mentioned COLL's DETERX technology - but, did NOT!

[floblu14]

FWIW - Brandywine Global Investment Management LLC Has $5.21 Million Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Brandywine Global Investment Management LLC grew its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Rating) by 19.9% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 325,262 shares of the specialty pharmaceutical company's stock after buying an additional 54,012 shares during the period. Brandywine Global Investment Management LLC owned approximately 0.97% of Collegium Pharmaceutical worth $5,211,000 as of its most recent filing with the SEC.

https://www.marketbeat.com/instant-alerts/nasdaq-coll-sec-filing-2023-03-03/

[floblu14]

Q4 2022 Collegium Pharmaceutical Inc Earnings Call Script -

https://finance.yahoo.com/news/q4-2022-collegium-pharmaceutical-inc-135203188.html

[floblu14]

COLL slide presentation - 2.23.2023

https://ir.collegiumpharma.com/static-files/3e57e043-794d-47ac-a59e-2a8a7493aae2

[floblu14]

Collegium Pharmaceutical, Inc. Prices Upsized $210.0 Million Convertible Senior Notes Offering
February 7, 2023

Exccerpts:
STOUGHTON, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the pricing of its offering of $210,000,000 aggregate principal amount of 2.875% convertible senior notes due 2029 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously announced offering size of $175,000,000 aggregate principal amount of notes. Collegium also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $31,500,000 principal amount of notes. The sale of the notes to the initial purchasers is expected to settle on February 10, 2023, subject to customary closing conditions.

The initial conversion rate is 27.3553 shares of common stock per $1,000 principal amount of notes, which represents an initial conversion price of approximately $36.56 per share of common stock. The initial conversion price represents a premium of approximately 30% over the last reported sale price of $28.12 per share of Collegium’s common stock on February 7, 2023. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events.

Read more:
https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-pharmaceutical-inc-prices-upsized-2100-million

[floblu14]

BlackRock Increases Position in Collegium Pharmaceutical (COLL)
January 30, 2023

Fintel reports that BlackRock has filed a 13G/A form with the SEC disclosing ownership of 5.73MM shares of Collegium Pharmaceutical Inc (COLL). This represents 17.1% of the company.

In their previous filing dated January 28, 2022 they reported 5.63MM shares and 16.30% of the company, an increase in shares of 1.77% and an increase in total ownership of 0.80% (calculated as current - previous percent ownership).

Analyst Price Forecast Suggests 29.80% Upside

As of January 26, 2023, the average one-year price target for Collegium Pharmaceutical is $36.72. The forecasts range from a low of $33.33 to a high of $42.00. The average price target represents an increase of 29.80% from its latest reported closing price of $28.29.

The projected annual revenue for Collegium Pharmaceutical is $562MM, an increase of 55.28%. The projected annual EPS is $1.58.

https://www.nasdaq.com/articles/blackrock-increases-position-in-collegium-pharmaceutical-coll

[floblu14]

INVESTOR PRESENTATION - JANUARY 2023

https://ir.collegiumpharma.com/static-files/845f6cea-2586-4ca0-a109-a9a074fe03de

[floblu14]

Collegium Pharmaceutical (COLL) PT Raised to $33 at Truist Securities from $26.

https://www.streetinsider.com/Analyst+PT+Change/Collegium+Pharmaceutical+%28COLL%29+PT+Raised+to+%2433+at+Truist+Securities/21042862.html

[floblu14]

That's it??

Collegium Pharmaceutical price target raised to $35 from $34 at Needham

Needham analyst Serge Belanger raised the firm's price target on Collegium Pharmaceutical to $35 from $34 and keeps a Buy rating on the shares. The company's 2023 guidance was above consensus and reflects its strong execution in managing its product portfolio while highlighting the improvements with its Xtampza GTN, the analyst tells investors in a research note.

Flo estimate - $58 PPS - Dec. 31, 2023

[floblu14]

Collegium Provides 2023 Financial Guidance
January 4, 2023

– Product Revenues, Net Expected in the Range of $565.0 Million to $580.0 Million –

– Adjusted Operating Expenses* Expected in the Range of $135.0 Million to $145.0 Million –

– Adjusted EBITDA* Expected in the Range of $355.0 Million to $370.0 Million –

– $100 Million Share Repurchase Program Authorized by the Board of Directors –

STOUGHTON, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced its 2023 full-year financial guidance and provided a business update.

“2022 was a pivotal year for Collegium. We achieved the first two phases of our Three Phase Action Agenda, which included integrating BDSI, completing Xtampza® ER contract renegotiations to ensure gross-to-net of less than 65%, and generating momentum across our differentiated and distinctly positioned pain portfolio,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium. “With these accomplishments, 2023 is set to be a banner year. We are focused on executing Phase 3, Accelerate, building our leadership position in responsible pain management, and deploying capital to maximize shareholder value.”

“Driven by Xtampza ER and Belbuca®, we expect to immediately accelerate revenue growth making 2023 a banner year for Collegium. With our fully synergized cost structure, we expect significant bottom-line expansion, with adjusted EBITDA expected to grow at over four times the rate of adjusted operating expenses,” said Colleen Tupper, Chief Financial Officer of Collegium. “We are committed to deploying capital in a disciplined manner with business development as our highest priority. We plan to continue rapidly paying down debt and opportunistically returning capital to shareholders through our new $100 million share repurchase program.”

Recent Business Highlights

Collegium’s board of directors authorized a new share repurchase program for 2023 to repurchase up to $100 million in common stock
Returned $19.1 million in capital to shareholders in 2022 under the share repurchase program authorized by Collegium’s board of directors in August 2021, including $4.0 million repurchased since November 3, 2022
In December 2022, the Federal Circuit upheld the judgment of the U.S. District Court for the District of Delaware that certain claims of the patents protecting Belbuca are valid. Collegium expects that, by virtue of the Federal Circuit’s decision, Alvogen will be barred from entering the market with its product until 2032
Completed Xtampza ER contract renegotiations in 2022, maintaining broad access while significantly decreasing rebates; Xtampza ER gross-to-net is expected to be in the range of 61% to 63% in 2023
Financial Guidance for 2023

Product revenues, net are expected in the range of $565.0 million to $580.0 million
Adjusted operating expenses (excluding stock-based compensation) are expected in the range of $135.0 million to $145.0 million
Adjusted EBITDA (excluding stock-based compensation) is expected in the range of $355.0 million to $370.0 million
* Non-GAAP financial measure. Please refer to the “Non-GAAP Financial Measures” section for details regarding these measures.

[floblu14]

Excellent revamped web site -

https://www.collegiumpharma.com/

Current job openings:

https://boards.greenhouse.io/collegiumpharma

[floblu14]

Appeals Court Affirms Validity of Collegium’s Belbuca® Patents
December 22, 2022 at 8:00 AM EST
Ruling bars ANDA filer Alvogen from entering market until 2032 patent expiry

STOUGHTON, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the Federal Circuit has upheld the judgment of the U.S. District Court for the District of Delaware that certain claims of the patents protecting Belbuca® are valid.

In addition to upholding the District Court’s judgment regarding the validity of certain claims in the 8,147,866 patent, expiring in 2027 (the “’866 patent”), and 9,901,539 patent, expiring in 2032 (the “’539 Patent”), the Federal Circuit vacated the District Court’s findings of invalidity with respect to certain claims of the ‘866 patent and the 9,655,843 patent (both expiring in 2027) and remanded such claims for reconsideration by the District Court.

Alvogen conceded infringement of all claims at issue in the litigation, and accordingly, Collegium expects that, by virtue of the Federal Circuit’s decision, Alvogen will be barred from entering the market with its product until 2032.

“We are very pleased with the Federal Circuit’s decision, which reinforces the strength of the patents supporting Belbuca, and we look forward to continuing to supply this innovative and differentiated product to appropriate patients,” said Shirley Kuhlmann, General Counsel and Chief Administrative Officer of Collegium.

https://ir.collegiumpharma.com/news-releases/news-release-details/appeals-court-affirms-validity-collegiums-belbucar-patents

[floblu14]

December 16 Friday -

Block Trade Count.......3
Bid[3] / Ask [1]........$22.71/22.75
Day Range.............$22.09-22.79
Last Trade Size.......544,387

Significant amount of shares sold/purchased at the close.

COLL continues to buy back shares with $45M remaining?? UP, up, UP!

[floblu14]

STSA—(-81%)—fails again in acute migraine:
https://www.globenewswire.com/news-release/2022/11/14/2554800/0/en/Satsuma-

Pharmaceuticals-Announces-Topline-Results-from-SUMMIT-Phase-3-Trial-of-STS101-for-the-Acute-Treatment-of-Migraine.html

STS101 was not statistically superior to placebo at two hours post-administration on the co-primary endpoints of freedom from pain and most bothersome symptom

[floblu14]

New SEEKING ALPHA report on COLL - NOVEMBER 9

My Thoughts on Q3
If I had to give you one takeaway from Collegium’s third-quarter earnings, it would be that the company is able to execute and make progress in every facet of their business. The earnings revealed that their business development efforts have been outstanding. The BDSI deal has been a seamless integration. The addition of the BDSI products helped deliver record net revenue and adjusted EBITDA. The company mentioned they will continue to evaluate additional assets that are “commercial stage opportunities with peak sales potential of over $150M” and are “differentiated with exclusivity that runs into the 2030s.”

On the commercial side, the renegotiation of Xtampza ER contracts will improve the gross-to-net of 54% of their prescription starting in January 2023, which should instantaneously speed up top-line growth. Next year they will renegotiate with plans that constitute an additional 30% of all prescriptions, so there is room for improvement in the future.

On the financial front, the company’s strong financial position is bolstered by hearty cash generation that has allowed them to promptly pay down debt. In fact, Collegium anticipates paying down $100M in debt by March of next year and will fully pay off the Pharmakon loan by March 2026. Into the bargain, the company is returning value to their shareholders with a $100M share repurchase program.

Overall, I believe Collegium’s Q3 earnings show that Collegium has once again made progress to hit their strategic, operational, and financial goals to ensure long-term growth.

READ MORE:
https://seekingalpha.com/article/4555193-collegium-pharmaceutical-stock-changing-strategy-after-q3-earnings-beat

[floblu14]

SHORT SQUEEZE - with 3M shorts outstanding & 17 days to recover - what does that tell you?

[floblu14]

Say what? Upcoming clinical trial? Might be a new acquisition soon -

Director, Clinical Operations

The Director, Clinical Operations will provide leadership to all operations functions assigned to the implementation of a clinical trial and represents clinical operations functions as a core member of the cross-functional team. This position is responsible and accountable for all operational activities within a clinical trial and ensures these activities are performed according to quality, schedule and cost standards as defined by senior management, executed contractual agreements, regulations, good clinical practice, and standard operating procedures (SOPs). Through appropriate leadership, direction and operational expertise, the Director will contribute to clinical operations strategies for specific projects and act as a key partner with internal and external stakeholders to ensure the effective implementation of these strategies.

Read more:
https://careers-collegiumpharma.icims.com/jobs/1539/director%2c-clinical-operations/job

[floblu14]

Collegium Announces 11 Poster Presentations at PAINWeek 2022 National Conference
August 30, 2022 at 8:00 AM EDT
STOUGHTON, Mass., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that 11 poster presentations highlighting data regarding its product portfolio will be presented at the Annual PAINWeek National Conference, taking place September 6-9, 2022 in Las Vegas, NV.

“Collegium is excited to support 11 posters regarding our meaningfully differentiated product portfolio that will be presented at PAINWeek 2022 National Conference,” said Thomas Smith, MD, EVP and Chief Medical Officer of Collegium. “We welcome opportunities to share clinical and real-world data with the medical community as part of our commitment to make a positive difference in the lives of people living with serious medical conditions.”

Poster Presentations:

Poster Title: Budget Impact Analysis of Xtampza® ER (oxycodone extended-release) for the Treatment of Chronic Pain from a Managed Care Perspective
Authors: Alan G. White, Todd Kunkel, Mancia Ko, Hongjue Wang

Poster Title: Treatment Effects of Celecoxib Oral Solution in Migraine with Aura and Without Aura: Post-HOC Analysis of Results from Two Randomized, Double-Blind Placebo-Controlled Trials
Authors: Stewart Tepper, Daniel Serrano, Mancia Ko, Todd Kunkel, Richard B. Lipton

Poster Title: Consistency of Response to Liquid Celecoxib in Adults with Migraine: Post HOC Analysis of Results from Two Randomized, Placebo-Controlled Studies
Authors: Daniel Serrano, Stewart Pepper, Mancia Ko, Todd Kunkel, Richard B. Lipton

Poster Title: Efficacy of Celecoxib Oral Solution in Adults with and Without Baseline Nausea: Post-HOC Analysis of Results from Two Randomized, Double-Blind Placebo-Controlled Trials in the Acute Treatment of Migraine
Authors: Richard B. Lipton, Daniel Serrano, Mancia Ko, Todd Kunkel, Stewart Pepper

Poster Title: Celecoxib Oral Solution in the Acute Treatment of Migraine: Pooled Efficacy and Safety Results From 2 Randomized Placebo-controlled Trials
Authors: Stewart Pepper, Harvey Kushner, Mancia Ko, Todd Kunkel, Richard B. Lipton

Poster Title: Impact of Celecoxib Oral Solution on Symptomatic Improvements in the Acute Treatment of Migraine
Authors: Stewart Pepper, Harvey Kushner, Mancia Ko, Todd Kunkel

Poster Title: Prescription Opioid Nonmedical Use via Oral Manipulation: An Under-Recognized Risk
Authors: Jody L. Green, Taryn Dailey-Govoni, Suzanna K. Vosburg

Poster Title: Association between per capita prescribing and abuse of tapentadol and other opioids among individuals entering treatment for opioid use disorders
Authors: Stevan Geoffrey Severtson, Annika M. Czizik, Matthew Ellis, Joshua C. Black, Janetta Iwanicki, Richard C. Dart

Poster Title: Non-Medical Use of XTAMPZA ER: Motivation, Methods, and Perceptions of Tampering
Authors: Joshua C. Black, Karilynn M. Rockhill, S. Geoff Severtson, Richard C. Dart

Poster Title: Cross-sectional Study of Tampering in an Abuse-Deterrent Formulation of an Extended-Release Opioid in a Treatment Center Population
Authors: Jennifer Jewell, Joshua Black, Matthew Ellis, Heather Olsen, Janetta Iwanicki, Richard Dart

Poster Title: Differences in the severity of medical outcomes of exposures reported to poison centers involving XTAMPZA® ER and other opioid analgesics
Authors: Stevan Geoffrey Severtson, Joshua C. Black, Janetta Iwanicki, Richard C. Dart

https://ir.collegiumpharma.com/news-releases/news-release-details/collegium-announces-11-poster-presentations-painweek-2022

Refer to PAIN WEEK -
https://www.painweek.org/

[floblu14]

Collegium Pharmaceutical, Inc. (COLL) CEO Joseph Ciaffoni on Q2 2022 Results - Earnings Call Transcript - Seeking Alpha

Excerpt:
Our top priority is business development. We are committed to taking a disciplined approach, but we believe current market conditions are conducive to potentially getting a deal done. We are actively evaluating commercial-stage opportunities, with peak sales potential of greater than $150 million. Importantly, we are looking for assets that are differentiated and with exclusivity that runs into the 2030s.

https://seekingalpha.com/article/4530920-collegium-pharmaceutical-inc-coll-ceo-joseph-ciaffoni-on-q2-2022-results-earnings-call

[floblu14]

Feel good? LOL

[floblu14]

Is COLL next? Again, why did Colleen Tupper come from Takeda to a small pharm - COLL??
https://www.collegiumpharma.com/people/colleen-tupper/

Mergers and acquisitions are starting to ramp up in Massachusetts' life sciences sector, but analysts believe the biggest buys are yet to come.

Most of the transactions involving local companies comprise small Boston-area firms being snapped up by larger biopharmaceutical companies. Epizyme Inc. (Nasdaq: EPZM), for instance, agreed to be acquired by French drugmaker Ipsen SA in June after years of lagging revenues. Similarly, New York drugmaker Regeneron Pharmaceuticals Inc. (Nasdaq: REGN) signed a deal to acquire local startup Checkmate Pharmaceuticals Inc. (Nasdaq: CMPI) in April, about a year and a half after Checkmate held an underwhelming IPO.

Since late last year, analysts have expected Big Pharma to use some of its funds — about $1.2 trillion, collectively, according to a research note from Geoffrey Porges at SVB Leerink — to buy smaller biotechs. Some of their predictions have come true: Vertex Pharmaceuticals Inc. (Nasdaq: VRTX), for instance, recently used some of its cash to buy a cell therapy competitor, ViaCyte, for $320 million.

There's still opportunity for bigger acquisitions, analysts say. SVB Leerink expects companies to deploy their funds "for more sizeable acquisitions" in the coming years. Ernst & Young LLC put out a report in January suggesting that cell therapies, antibody-drug conjugates and RNA- and DNA-based medicines would be areas of interest for such transactions this decade.

"These (larger) companies have always relied on early biotech companies for innovation," Ernst & Young senior life sciences advisor Barbara Ryan recently told the Business Journal. "They have record levels of firepower to fund M&A, strategic partnerships, et cetera."

Now, she says, it's a question of how to value the technologies that underpin smaller startups.

Just five Massachusetts-based life sciences companies have made acquisitions this year. Most recently, synthetic biology firm Ginkgo Bioworks Holdings Inc. (NYSE: DNA) bought a competitor, Zymergen Inc., in an all-stock transaction valuing the California company at $300 million. The deal is Ginkgo's largest acquisition to date, and while CEO and co-founder Jason Kelly doesn't see another deal of that size on the immediate horizon, he believes M&A will be a key component of the company's strategy going forward, in addition to the many partnerships that already form the foundation of Ginkgo's business model.

In some cases, acquisitions are strategic ways to extend a company's cash runway. Syros Pharmaceuticals (Nasdaq: SYRS), for instance, agreed in July to acquire a New Jersey biotech firm called Tyme Technologies Inc. (Nasdaq: TYME), raising about $60 million through the combination.

"The overall biotech markets are in sort of an unprecedented poor state," CEO Nancy Simonian said at the time. "Looking for creative ways to finance what's important, we explored a range of strategic financing options. Our goal was to raise sufficient capital to fund our operations well beyond some upcoming significant milestones."

Other local firms that have made acquisitions include Boston Scientific Corp. (NYSE: BSX), which bought a Korean medtech manufacturer for $230 million; Collegium Pharmaceutical Inc. (Nasdaq: COLL), which bought a Raleigh, N.C.-based competitor called BioDelivery Sciences International Inc. (Nasdaq: BDSI) for $604 million; and Intellia Therapeutics Inc. (Nasdaq: NTLA), which bought a little-known University of California-Berkeley spinout called Rewrite Therapeutics in a deal worth up to $200 million.

https://finance.yahoo.com/m/998cb27f-c6e9-3fbc-ae42-5ac4ad37021c/mass-m-a-activity-picks-up.html

[floblu14]

7 sale positions listed of which 4 are posted today -

https://careers-collegiumpharma.icims.com/jobs/search

Most likely - BELBUCA & ELYXYB from BIOSCIENCE are selling well.

[floblu14]

Reading between the lines - I'm guessing that something is in the works for another acquisition -

In job listings, there are a number of "clinical trial" references. Considering there are NO titles for research scientists, etc. - me thinks they are on the threshold of another acquisition. Possibly - in the neurological field to complement their migraine drug.

Examples out of a total of 22 new career opportunities -

A. Senior Manager, Scientific Communications
Some knowledge and understanding of the pharmaceutical clinical development and commercialization process
Familiarity with regulatory and legal guidelines regarding medical communications strategy and execution

https://careers-collegiumpharma.icims.com/jobs/1542/senior-manager%2c-scientific-communications/job

B. Vice President, Regulatory Affairs
Represent the Company and the Regulatory Affairs team in interactions (both in writing and in person) with Health Authorities (i.e., HHS, FDA, CMC, DEA, etc.), CROs, Investigator Meetings, Advisory Boards, and to all stakeholders.

Minimum of 5-7 years of Industry (Pharmaceutical or Life Science) experience required; minimum of 4 years specifically in Regulatory Affairs. Knowledge of Commercial support, CMC, and a track record of having worked on teams towards successful submissions and license approvals with CDER or CBER required.

https://careers-collegiumpharma.icims.com/jobs/1541/vice-president%2c-regulatory-affairs/job

C. Regulatory Affairs Manager

This role will be the single point of contact between the Company and Health Authorities such as the Food and Drug Administration (FDA), Health Canada, and the European Medicines Agency (EMA). They will work in a highly cross-functional manner with internal stakeholders including Clinical, Commercial, Technical Operations, and Quality Assurance to file and maintain the applications for Collegium’s marketed products and development programs in compliance with applicable regulations.

Influence and contribute to the short and long term Regulatory planning of new product opportunities

https://careers-collegiumpharma.icims.com/jobs/1513/regulatory-affairs-manager/job

See other listings, also --
https://careers-collegiumpharma.icims.com/jobs/search?pr=0&schemaId=&o=

COMMENTS?

[floblu14]

New COLL administer as of May 2022 -


Kelly Clements
CHIEF PEOPLE OFFICER
Kelly Clements joined Collegium in May 2022 as Vice President and Chief People Officer. She has over 20 years of industry experience as an HR leader in the pharmaceutical industry. Most recently, Ms. Clements served as the Vice President of US People & Organization at Zealand Pharmaceuticals, where she was responsible for aligning communications, strategy, structure, people and processes to advance Zealand’s culture and optimize and drive business outcomes. Prior to Zealand, Ms. Clements held roles of rising responsibility at Foundation Medicine, Sage Therapeutics, Alkermes, and Biogen. She has demonstrated success in supporting the implementation of business strategy, the execution of business objectives and the management of employee engagement while leading organizations through pivotal times of growth and transformation.

Ms. Clements received a Bachelors in Accounting & Finance from Bridgewater State and a Masters in Human Resource Management from Emmanuel College.

[floblu14]

Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock? 7/6/2022

Investors in Collegium Pharmaceutical, Inc. COLL need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 16, 2022 $2.50 Call had some of the highest implied volatility of all equity options today.

What is Implied Volatility?
Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.

What do the Analysts Think?
Clearly, options traders are pricing in a big move for Collegium Pharmaceutical shares, but what is the fundamental picture for the company?

https://finance.yahoo.com/news/options-market-predicting-spike-collegium-151903092.html

[floblu14]

Collegium Pharmaceutical: Oversold And Cheap
Jun. 12, 2022 6:35 AM ETCollegium Pharmaceutical, Inc. (COLL)1 Comment

Summary
Shares of pain management drug concern Collegium Pharmaceutical have fallen over 40% as the biotech selloff, negative attitudes towards opiates, and patent cliffs have taken a toll.

The company's recent purchase of BioDelivery Sciences provides it with complementary suite of assets, an entry into neurology, and $75 million of cost synergies.

With high leverage expected to deflate by YE22 and currently trading at three times FY22E EPS, Collegium merited a deeper dive.

Today, we look at a small cap biopharma that appears oversold and also made a solid strategic acquisition. A full analysis and recommendation follow below.

COLL Stock Chart
Seeking Alpha

Company Overview
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is a Canton, Massachusetts based commercial-stage specialty drug concern focused on the development and marketing of therapies for pain management. With its March 2022 acquisition of BioDelivery Sciences International, the company now has five commercial products, including one neurology (acute migraine) asset and one anti-constipation remedy. Collegium was formed in 2002, pivoted to its current pain management concentration in 2010, and went public in 2015, raising net proceeds of $72.0 million at $12 per share. Its stock trades just over $16.00 a share, translating to a market cap of $560 million.

Xtampza ER. The company's only FDA-approved therapy that it didn't acquire is Xtampza ER, which is extended-release oxycodone for the management of pain severe enough to require around-the-clock, long-term opioid treatment for which alternatives are inadequate. This product leverages Collegium's abuse-deterrent technology dubbed DETERx. The platform combines active ingredients (in this case oxycodone) with fatty acid and waxes to form microsphere beads that are resistant to physical or chemical manipulation, promoting ER. As such, Xtampza ER capsule has received oral, intranasal, and intravenous abuse-deterrent labeling. It was approved and launched in 2016 and generated FY21 net sales of $103.7 million, representing a ~34% share of the oxycodone ER market. It is patent-protected until September 2033.

Nucynta. Prior to its purchase of BioDelivery, Collegium's only other commercial assets were its Nucynta ER and Nucynta IR (immediate-release) products, which are different formulations of the opioid pain therapy tapentadol. The prior is approved for the same indication as Xtampza ER, while the latter is approved for acute pain severe enough to require an opioid analgesic and for which alternatives are inadequate. Furthermore, Nucynta ER is the only ER drug indicated for pain associated with diabetic peripheral neuropathy. The company initially marketed Nucynta products on behalf of Assertio Holdings (ASRT), but then acquired the assets for a total consideration of $375 million in February 2020. Nucynta products generated FY21 net revenue of $173.2 million, but their exclusivity ends in July 2025.

Belbuca. In March 2022, Collegium bolstered its pain management portfolio through its purchase of BioDelivery, whose primary revenue generator is buccal film Belbuca. The Schedule III opioid, formerly a competitor and now compliment in the company's portfolio, represents a second growing pain med alongside Xtampza ER. It generated FY21 net revenue of $148.2 million, but its exclusivity ends in January 2027.

Collegium Pharmaceutical Purchase Rationale
May Company Presentation

Together, Belbuca, Xtampza ER, and Nucynta ER have approximately 50% share of the branded opioid ER market.

Symproic. Opioid-induced constipation [OIC] is a frequent side effect of long-term opioid use, afflicting 40-80% of patients. For this outcome, BioDelivery markets Symproic, which was in-licensed for the U.S. market from Shionogi (OTCPK:SGIOF) in 2019. This therapy generated FY21 net revenue of $16.4 million.

Elyxyb. Also part of the BioDelivery deal is acute migraine remedy Elyxyb (celecoxib), an oral Cox-2 NSAID that was approved in 2020 and launched in February 2022. It carries a boxed warning for serious risk of cardiovascular and gastrointestinal [GI] events. With that said, BioDelivery believes its therapy causes fewer GI issues than the other FDA-approved acute migraine NSAID: Assertio's Cambia (diclofenac potassium). It enjoys patent protection through 2036. The domestic opportunity is significant with the acute migraine market reaching $2.8 billion in 2021, with over 18.1 million prescriptions written, up 8% from 2020. With that said, the company will implement a targeted approach for Elyxyb's launch, and use learnings to instruct next steps, while it looks to onboard other neurology assets.

BioDelivery Acquisition

Beyond the three therapies, Collegium received a sales effort consisting of 147 sales reps, 17 regional managers, and three area directors from BioDelivery as part of the $604 million all-cash transaction. Unquestionably, many of these employees will be let go as the company right sizes the combined commercial operations, which Collegium expects to result in cost synergies amounting to a run rate of $75 million twelve months post-close.

1Q22 Results & Outlook

In addition to the BioDelivery acquisition, Collegium executed a settlement covering all 27 opioid-related lawsuits against it at a cost of $2.75 million in March 2022, making it a busy month for the company.

On May 10, 2022, with eight days of BioDelivery sales in its results, Collegium reported non-GAAP 1Q22 EPS of $0.60 and Adj. EBITDA of $43.5 million on revenue of $83.8 million versus earnings of $0.55 a share (non-GAAP) and Adj. EBTIDA of $45.3 million on revenue of $87.7 million in 1Q21. These numbers were slightly better than Street expectations but it is unlikely that the consensus included BioDelivery's contribution.

More importantly, Belbuca and Xtampza ER registered year-over-year prescription growth and market share gains in the stanza. Belbuca scripts were up 4% while its share of the branded ER market increased two points to 17.4%. Xtampza ER prescriptions were up 3% and its share of the oxycodone ER market grew 3.6 percentage points to 34.2%. Furthermore, Nucynta ER maintained a 5.6% share of the branded ER market while Symproic scripts grew 14% year-over-year.

With BioDelivery under its roof, management reiterated a FY22 forecast - first announced in early April 2022 - that included Adj. EBITDA of $242.5 million on revenue of $457.5 million, based on range midpoints.

The market, in the throes of a major selloff, took the news in stride with shares of COLL down $0.02 to $14.46 in the subsequent (May 11th, 2022) trading session.

Balance Sheet & Analyst Commentary
To acquire BioDelivery, Collegium onboarded additional debt of $650 million, bringing its total to $768.6 million against cash of $106.7 million for net leverage of 6.7. However, that metric should drop below 3.0 by YE22 (assuming no more purchases) as EBITDA is expected to more than double in FY22. The company has $52.1 million remaining on a share repurchase program, but it appears that its capital allocation priority - despite its depressed share price - is to find a neurology asset to complement Elyxyb.

Collegium Pharmaceutical Balance Sheet
May Company Presentation

In the subpopulation of Street analysts offering commentary during 2022 - no comments were made during 2021 - sentiment is bullish with two buy and two outperform ratings and a median twelve-month price objective of $32.50. Overall, expectations are for Collegium to earn $5.30 a share (non-GAAP) on revenue of $448.7 million in FY22, followed by $7.10 per share (non-GAAP) on revenue of $542.0 million in FY23, representing 34% and 21% gains, respectively.

Verdict
Collegium has a significant debt overhang and two of its three best selling assets are facing patent cliffs in the next three to five years and has no clinical pipeline. Furthermore, opioids are not exactly popular with the public or investors. With that said, it is trading at a rather eye-popping three times FY22E EPS and 2.2x FY23E EPS, meaning the company is on track to earn approximately double its market cap from 2022-2025. On that metric alone, its stock is a buy. Looked at another way, the company could pay down its debt and buy all of its stock back in four to five years. Major market selloffs create pricing dislocations. Collegium is representative of that maxim.

https://seekingalpha.com/article/4517947-collegium-pharmaceutical-oversold-and-cheap

[floblu14]

Needham Thinks Collegium Pharmaceutical’s Stock is Going to Recover

Needham analyst Serge Belanger maintained a Buy rating on Collegium Pharmaceutical (COLL – Research Report) today and set a price target of $36.00.
https://ih.advfn.com/stock-market/NASDAQ/collegium-pharmaceutical-COLL/stock-news/88075196/needham-thinks-collegium-pharmaceutical-s-stock-i

21 New Career listings:
https://careers-collegiumpharma.icims.com/jobs/search?pr=0&schemaId=&o=

[floblu14]

Collegium Pharmaceutical (COLL) Received its Third Buy in a Row
April 14 2022 - 05:45AM

After William Blair and H.C. Wainwright gave Collegium Pharmaceutical (NASDAQ: COLL) a Buy rating last month, the company received another Buy, this time from Needham. Analyst Serge Belanger maintained a Buy rating on Collegium Pharmaceutical today and set a price target of $36.00. The company's shares closed last Wednesday at $19.51. According to TipRanks.com, Belanger is a 4-star analyst with an average return of 6.2% and a 46.6% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and KalVista Pharmaceuticals. Collegium Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $28.00, which is a 45.

https://www.tipranks.com/news/blurbs/collegium-pharmaceutical-coll-received-its-third-buy-in-a-row-2?utm_source=advfn.com&utm_medium=referral

[floblu14]

AGAIN -

Collegium Pharmaceutical price target raised to $42 from $36 at Piper Sandler 02/22 COLL, BDSI Piper Sandler analyst David Amsellem raised the firm's price target on Collegium Pharmaceutical (COLL) to $42 from $36 and keeps an Overweight rating on the shares following the BioDelivery Sciences (BDSI) acquisition announcement. The analyst believes that visibility into EBITDA in excess of $300M by 2023 is relatively high.

Read more at:
https://thefly.com/n.php?id=3463057

[floblu14]

Thomas B. Smith, M.D., FAAFP

CHIEF MEDICAL OFFICER
Dr. Thomas Smith joined Collegium Pharmaceutical in March of 2022 following the acquisition of BioDelivery Sciences International. Dr. Smith has more than twenty-five years of experience in a variety of leadership roles at various major pharmaceutical companies including serving as the Chief Medical Officer for BioDelivery Sciences International, Charleston Laboratories, Ameritox, and Mallinckrodt Pharmaceuticals. Prior to these, Dr. Smith served in scientific, medical, and clinical leadership roles at Abbott Laboratories, Teva Pharmaceuticals, and Kendle International. He is a member of several medical and scientific societies, including the American Medical Association and the American Academy of Family Physicians. Dr. Smith earned his M.D. from the Indiana University School of Medicine and a B.S. from Purdue University.

https://www.collegiumpharma.com/people/thomas-b-smith-m-d-faafp/

[floblu14]

Hey, hey, HEY -

Web site now lists 6 FDA approved products:

https://www.collegiumpharma.com/our-products/

[floblu14]

ELYXYB home page -

https://www.elyxyb.com/